Miles D. Houslay

Miles D. Houslay's AcademicInfluence.com Rankings

Miles D. Houslay

Biology

#5292

World Rank

#7737

Historical Rank

Biochemistry

#612

World Rank

#704

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Miles D. Houslay Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Miles D. Houslay's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. (2003) (772)
DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling (2005) (669)
Keynote review: phosphodiesterase-4 as a therapeutic target. (2005) (598)
Behavioral Phenotypes of Disc1 Missense Mutations in Mice (2007) (554)
mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module (2001) (496)
Tailoring cAMP-signalling responses through isoform multiplicity. (1997) (449)
Disrupted-in-Schizophrenia-1 (DISC1) regulates spines of the glutamate synapse via Rac1 (2010) (413)
Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. (2010) (407)
The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. (2002) (401)
Fluorescence Resonance Energy Transfer–Based Analysis of cAMP Dynamics in Live Neonatal Rat Cardiac Myocytes Reveals Distinct Functions of Compartmentalized Phosphodiesterases (2004) (391)
Sleep deprivation impairs cAMP signaling in the hippocampus (2009) (361)
Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis (2010) (354)
Cholesterol is excluded from the phospholipid annulus surrounding an active calcium transport protein (1975) (347)
Targeting of Cyclic AMP Degradation to β2-Adrenergic Receptors by β-Arrestins (2002) (343)
Retraction for Baillie et al., β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi (2003) (331)
Normal p21N-ras couples bombesin and other growth factor receptors to inositol phosphate production (1986) (331)
cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. (2007) (330)
Activation of two signal-transduction systems in hepatocytes by glucagon (1986) (326)
The RACK1 Signaling Scaffold Protein Selectively Interacts with the cAMP-specific Phosphodiesterase PDE4D5 Isoform* (1999) (311)
A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. (1997) (298)
'Crosstalk': a pivotal role for protein kinase C in modulating relationships between signal transduction pathways. (1991) (296)
The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. (1998) (289)
Compartmentalized Phosphodiesterase-2 Activity Blunts &bgr;-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway (2006) (287)
Annular lipids determine the ATPase activity of a calcium transport protein complexed with dipalmitoyllecithin. (1976) (281)
The MAP kinase ERK2 inhibits the cyclic AMP‐specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579 (1999) (262)
Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A‐mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1) (2002) (258)
The increase in bilayer fluidity of rat liver plasma membranes achieved by the local anesthetic benzyl alcohol affects the activity of intrinsic membrane enzymes. (1980) (247)
ERK2 Mitogen-activated Protein Kinase Binding, Phosphorylation, and Regulation of the PDE4D cAMP-specific Phosphodiesterases (2000) (238)
PDE4 cAMP-specific phosphodiesterases. (2001) (237)
Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. (2002) (233)
RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with βArrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the β2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells* (2005) (225)
Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract (2005) (213)
DISC1-dependent switch from progenitor proliferation to migration in the developing cortex (2011) (209)
Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. (2000) (207)
Abolition of the expression of inhibitory guanine nucleotide regulatory protein Gi activity in diabetes (1987) (202)
Multiple forms of monoamine oxidase: fact and artefact. (1976) (200)
Protein Kinase A Type I and Type II Define Distinct Intracellular Signaling Compartments (2008) (194)
Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. (2011) (187)
A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes. (1974) (187)
Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. (1997) (186)
beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. (2003) (182)
The nature of the electrophoretically separable multiple forms of rat liver monoamine oxidase. (1973) (179)
PGE1 stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases (2006) (176)
Attenuation of the Activity of the cAMP-specific Phosphodiesterase PDE4A5 by Interaction with the Immunophilin XAP2* (2003) (171)
Sub‐family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP‐specific phosphodiesterases (2000) (168)
A Complex between FAK, RACK1, and PDE4D5 Controls Spreading Initiation and Cancer Cell Polarity (2010) (167)
Isoform-Selective Susceptibility of DISC1/Phosphodiesterase-4 Complexes to Dissociation by Elevated Intracellular cAMP Levels (2007) (166)
Derivation of Endothelial Cells From Human Embryonic Stem Cells by Directed Differentiation: Analysis of MicroRNA and Angiogenesis In Vitro and In Vivo (2010) (164)
Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1 (2016) (160)
Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. (2006) (159)
5‐Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats (1996) (157)
TAPAS-1, a Novel Microdomain within the Unique N-terminal Region of the PDE4A1 cAMP-specific Phosphodiesterase That Allows Rapid, Ca2+-triggered Membrane Association with Selectivity for Interaction with Phosphatidic Acid* (2002) (155)
cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. (1998) (153)
Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. (1997) (152)
The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function (2011) (149)
Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. (2007) (146)
Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. (2005) (146)
A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. (1980) (143)
Cyclic Nucleotide Phosphodiesterases in Health and Disease (2006) (141)
Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. (2000) (139)
Molecular mechanisms of transmembrane signalling (1985) (138)
Phosphorylation-dependent Interactions between ADAM15 Cytoplasmic Domain and Src Family Protein-tyrosine Kinases* (2002) (137)
TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling1 (2004) (136)
The Cardiac IKs Potassium Channel Macromolecular Complex Includes the Phosphodiesterase PDE4D3* (2009) (133)
The activity of glucagon-stimulated adenylate cyclase from rat liver plasma membranes is modulated by the fluidity of its lipid environment. (1978) (131)
Cyclic nucleotide phosphodiesterases : structure, regulation and drug action (1990) (130)
UCR1 and UCR2 Domains Unique to the cAMP-specific Phosphodiesterase Family Form a Discrete Module via Electrostatic Interactions* (2000) (121)
Insulin and glucagon regulate the activation of two distinct membrane-bound cyclic AMP phosphodiesterases in hepatocytes. (1983) (120)
Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. (1993) (120)
The lipid environment of the glucagon receptor regulates adenylate cyclase activity. (1976) (118)
EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation (2008) (118)
p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway (2007) (118)
Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. (1997) (116)
The glucagon receptor of rat liver plasma membrane can couple to adenylate cyclase without activating it. (1976) (114)
Membrane Localization of Cyclic Nucleotide Phosphodiesterase 3 (PDE3) (2000) (112)
Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. (2004) (111)
Platelet activating factor and U44069 stimulate a GTPase activity in human platelets which is distinct from the guanine nucleotide regulatory proteins, Ns and Ni. (1986) (111)
Dynamics of Biological Membranes: Influence on Synthesis, Structure and Function (1982) (110)
In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. (2005) (109)
Is an early calcium flux necessary to stimulate lymphocytes? (1977) (109)
The Unique Amino-terminal Region of the PDE4D5 cAMP Phosphodiesterase Isoform Confers Preferential Interaction with β-Arrestins* (2003) (109)
Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. (1995) (107)
Insulin triggers cyclic AMP-dependent activation and phosphorylation of a plasma membrane cyclic AMP phosphodiesterase (1980) (102)
Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. (1997) (101)
Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness (2007) (100)
Small Molecule AKAP-Protein Kinase A (PKA) Interaction Disruptors That Activate PKA Interfere with Compartmentalized cAMP Signaling in Cardiac Myocytes* (2010) (99)
The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). (1996) (98)
The phorbol ester, TPA inhibits glucagon‐stimulated adenylate cyclase activity (1984) (98)
Phosphorylation of RACK1 on Tyrosine 52 by c-Abl Is Required for Insulin-like Growth Factor I-mediated Regulation of Focal Adhesion Kinase* (2009) (96)
Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays. (2007) (95)
Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the β-agonist induced hypertrophic response in cardiac myocytes. (2011) (94)
Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. (2010) (94)
The Human Cyclic AMP-specific Phosphodiesterase PDE-46 (HSPDE4A4B) Expressed in Transfected COS7 Cells Occurs as Both Particulate and Cytosolic Species That Exhibit Distinct Kinetics of Inhibition by the Antidepressant Rolipram* (1996) (94)
The reaction pathway of membrane-bound rat liver mitochondrial monoamine oxidase. (1973) (94)
Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte‐macrophage differentiation of human U937 cells (2004) (92)
Hormonal regulation of Gi2 α-subunit phosphorylation in intact hepatocytes (1990) (92)
Cyclic AMP Phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a Vascular Endothelial Cadherin (VE-Cad)-based Signaling Complex and Controls cAMP-mediated Vascular Permeability* (2010) (92)
The insulin receptor tyrosyl kinase phosphorylates holomeric forms of the guanine nucleotide regulatory proteins Gi and Go (1987) (92)
Cyclic AMP-dependent Transcriptional Up-regulation of Phosphodiesterase 4D5 in Human Airway Smooth Muscle Cells (2002) (90)
Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. (2007) (90)
Allotopic properties of human brain monoamine oxidase. (1973) (88)
Adaptation in cyclic AMP signalling processes: a central role for cyclic AMP phosphodiesterases. (1998) (87)
Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. (1995) (84)
Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. (1997) (83)
Alternative Splicing of cAMP-specific Phosphodiesterase mRNA Transcripts (1996) (82)
Changes in the form of Arrhenius plots of the activity of glucagon-stimulated adenylate cyclase and other hamster liver plasma-membrane enzymes occurring on hibernation. (1978) (81)
Elevated membrane cholesterol concentrations inhibit glucagon-stimulated adenylate cyclase. (1983) (78)
Tyrosine 302 in RACK1 Is Essential for Insulin-like Growth Factor-I-mediated Competitive Binding of PP2A and β1 Integrin and for Tumor Cell Proliferation and Migration* (2008) (78)
Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. (1994) (78)
The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways. (2003) (77)
Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). (2001) (75)
Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. (1996) (75)
Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10. (2001) (75)
Mdm2 Directs the Ubiquitination of β-Arrestin-sequestered cAMP Phosphodiesterase-4D5* (2009) (74)
The Activity of Adenylate Cyclase Is Regulated by the Nature of Its Lipid Environment (1983) (74)
Exchange of partners in glucagon receptor-adenylate cyclase complexes. Physical evidence for the independent, mobile receptor model. (1977) (74)
Inferring Signaling Pathway Topologies from Multiple Perturbation Measurements of Specific Biochemical Species (2010) (73)
Insulin exerts actions through a distinct species of guanine nucleotide regulatory protein: inhibition of adenylate cyclase. (1983) (72)
Identification of a surface on the beta-propeller protein RACK1 that interacts with the cAMP-specific phosphodiesterase PDE4D5. (2001) (72)
Purification and properties of the insulin-stimulated cyclic AMP phosphodiesterase from rat liver plasma membranes. (1981) (72)
Diabetes-induced alterations in the expression, functioning and phosphorylation state of the inhibitory guanine nucleotide regulatory protein Gi-2 in hepatocytes. (1990) (72)
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. (2007) (70)
The role of ventral striatal cAMP signaling in stress-induced behaviors (2015) (69)
MEK1 Binds Directly to βArrestin1, Influencing Both Its Phosphorylation by ERK and the Timing of Its Isoprenaline-stimulated Internalization* (2009) (69)
Constitutive Activation of Gαs within Forebrain Neurons Causes Deficits in Sensorimotor Gating Because of PKA-Dependent Decreases in cAMP (2007) (69)
β-Arrestin 1 Inhibits the GTPase-Activating Protein Function of ARHGAP21, Promoting Activation of RhoA following Angiotensin II Type 1A Receptor Stimulation (2010) (68)
Adenosine 3′,5′-Cyclic Monophosphate (cAMP)-Dependent Inhibition of IL-5 from Human T Lymphocytes Is Not Mediated by the cAMP-Dependent Protein Kinase A1 (2001) (68)
cAMP synthesis and degradation by phagosomes regulate actin assembly and fusion events: consequences for mycobacteria (2006) (68)
The unique N‐terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains (1999) (68)
Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes (2010) (65)
Cyclic AMP Controls mTOR through Regulation of the Dynamic Interaction between Rheb and Phosphodiesterase 4D (2010) (65)
The rapid desensitization of glucagon-stimulated adenylate cyclase is a cyclic AMP-independent process that can be mimicked by hormones which stimulate inositol phospholipid metabolism. (1987) (65)
Oxygen-dependent cleavage of the p75 neurotrophin receptor triggers stabilization of HIF-1α. (2011) (65)
Noradrenergic Activity Differentially Regulates the Expression of Rolipram‐Sensitive, High‐Affinity Cyclic AMP Phosphodiesterase (PDE4) in Rat Brain (1997) (64)
Protein kinase C isoforms play differential roles in the regulation of adipocyte differentiation. (1998) (63)
The insulin- and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity. (1987) (63)
Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase. (1995) (63)
Identification and Characterization of PDE4A11, a Novel, Widely Expressed Long Isoform Encoded by the Human PDE4A cAMP Phosphodiesterase Gene (2005) (63)
Determination of the Structure of the N-terminal Splice Region of the Cyclic AMP-specific Phosphodiesterase RD1 (RNPDE4A1) by 1H NMR and Identification of the Membrane Association Domain Using Chimeric Constructs* (1996) (63)
Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver. (1986) (63)
Insulin, glucagon and the receptor-mediated control of cyclic AMP concentrations in liver. Twenty-second Colworth medal lecture. (1986) (63)
Guanine-nucleotide-binding proteins expressed in rat white adipose tissue. Identification of both mRNAs and proteins corresponding to Gi1, Gi2 and Gi3. (1989) (62)
Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. (1998) (62)
Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/β-Arrestin/cAMP Phosphodiesterase 4 Complex (2010) (62)
Diabetes induces selective alterations in the expression of protein kinase C isoforms in hepatocytes (1993) (60)
Phenobarbital selectively modulates the glucagon-stimulated activity of adenylate cyclase by depressing the lipid phase separation occurring in the outer half of the bilayer of liver plasma membranes. (1981) (59)
Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. (2006) (58)
The action of islet activating protein (pertussis toxin) on insulin's ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes. (1986) (58)
PDE4B5, a Novel, Super-Short, Brain-Specific cAMP Phosphodiesterase-4 Variant Whose Isoform-Specifying N-Terminal Region Is Identical to That of cAMP Phosphodiesterase-4D6 (PDE4D6) (2007) (57)
A Phosphodiesterase 3B-based Signaling Complex Integrates Exchange Protein Activated by cAMP 1 and Phosphatidylinositol 3-Kinase Signals in Human Arterial Endothelial Cells* (2011) (57)
Cyclic nucleotide phosphodiesterases in Drosophila melanogaster. (2005) (57)
Insulin inhibits the cholera-toxin-catalysed ribosylation of a Mr-25000 protein in rat liver plasma membranes. (1985) (57)
Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. (2003) (56)
A high-fat diet promotes depression-like behavior in mice by suppressing hypothalamic PKA signaling (2019) (55)
Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. (2011) (54)
Dynamic Regulation, Desensitization, and Cross-talk in Discrete Subcellular Microdomains during β2-Adrenoceptor and Prostanoid Receptor cAMP Signaling* (2007) (54)
Thrombin, unlike vasopressin, appears to stimulate two distinct guanine nucleotide regulatory proteins in human platelets. (1986) (54)
In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting. (2002) (54)
Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation. (2011) (53)
Adenylate cyclase is inhibited upon depletion of plasma-membrane cholesterol. (1983) (53)
Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling. (2006) (53)
The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution. (2000) (52)
Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. (1998) (51)
Diabetes abolishes the GTP-dependent, but not the receptor-dependent inhibitory function of the inhibitory guanine-nucleotide-binding regulatory protein (Gi) on adipocyte adenylate cyclase activity. (1990) (50)
1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1. (2007) (50)
Phosphodiesterase-8A binds to and regulates Raf-1 kinase (2013) (50)
Challenge of hepatocytes by glucagon triggers a rapid modulation of adenylate cyclase activity in isolated membranes. (1983) (49)
Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. (1989) (49)
Forskolin and ethanol both perturb the structure of liver plasma membranes and activate adenylate cyclase activity. (1983) (49)
The phospholipid headgroup specificity of an ATP-dependent calcium pump. (1978) (49)
cAMP-specific phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique non-redundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling. (2007) (49)
Growth hormone and phorbol esters require specific protein kinase C isoforms to activate mitogen-activated protein kinases in 3T3-F442A cells. (1997) (48)
Regulation of adenylate cyclase (EC 4.6.1.1) activity by its lipid environment (1985) (46)
Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5 (2002) (46)
Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases (2019) (46)
Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). (2008) (46)
Rat liver mitochondrial monoamine oxidase. A change in the reaction mechanism on solubilization. (1975) (45)
Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579. (2006) (45)
Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. (2010) (45)
Egg activation unscrambles a potential role for IP4 (1987) (45)
PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases. (2008) (45)
The novel long PDE4A10 cyclic AMP phosphodiesterase shows a pattern of expression within brain that is distinct from the long PDE4A5 and short PDE4A1 isoforms. (2001) (44)
PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration (2004) (44)
Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs. (2008) (44)
Lipid phase transitions control β‐hydroxybutyrate dehydrogenase activity in defined‐lipid protein complexes (1975) (44)
A family of guanine nucleotide regulatory proteins (1984) (44)
Putting the lid on phosphodiesterase 4 (2010) (44)
High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. (2010) (44)
Metabolism of aldehydes in brain. (1977) (44)
Insulin: in search of a mechanism (1983) (43)
Mutant but not normal p21 ras elevates inositol phospholipid breakdown in two different cell systems. (1988) (43)
Glucagon-stimulated adenylate cyclase detects a selective perturbation of the inner half of the liver plasma-membrane bilayer achieved by the local anaesthetic prilocaine. (1980) (43)
Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis. (2014) (43)
Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. (2010) (42)
The activity of 5'-nucleotidase in liver plasma membranes is affected by the increase in bilayer fluidity achieved by anionic drugs but not by cationic drugs. (1982) (42)
p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. (2010) (42)
5‐Hydroxytryptamine is a substrate for both species of monoamine oxidase in beef heart mitochondria (1976) (42)
Altered G-protein expression and adenylate cyclase activity in platelets of non-insulin-dependent diabetic (NIDDM) male subjects. (1991) (41)
Characterization of the phosphorylated form of the insulin-stimulated cyclic AMP phosphodiesterase from rat liver plasma membranes. (1981) (41)
Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells. (2006) (41)
Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. (2003) (40)
Helix-1 of the cAMP-specific phosphodiesterase PDE4A1 regulates its phospholipase-D-dependent redistribution in response to release of Ca2+ (2006) (40)
Molecular cloning and expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IVA, cyclic AMP specific phosphodiesterase (hPDE-IVA-h6.1). (1994) (39)
Integrating Cardiac PIP 3 and cAMP Signaling through a PKA Anchoring Function of p 110 g (39)
Diabetes-induced changes in guanine-nucleotide-regulatory-protein mRNA detected using synthetic oligonucleotide probes. (1990) (39)
Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory (2016) (38)
Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression. (2008) (38)
PKA phosphorylation of p62/SQSTM1 regulates PB1 domain interaction partner binding. (2014) (38)
Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293beta2 cells and cardiac myocytes. (2006) (38)
Nuclear pore complex remodeling by p75NTR cleavage controls TGF-β signaling and astrocyte functions (2015) (37)
Islet-activating protein blocks glucagon desensitization in intact hepatocytes. (1984) (37)
Guanosine 5′-triphosphate and guanosine 5′-[βγ-imido]triphosphate effect a collision coupling mechanism between the glucagon receptor and catalytic unit of adenylate cyclase (1980) (37)
G-proteins in experimental hypertension: a study of spontaneously hypertensive rat myocardial and renal cortical plasma membranes (1993) (36)
Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. (1996) (36)
Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 (1995) (36)
Growth hormone decreases the response to anti-lipolytic agonists and decreases the levels of Gi2 in rat adipocytes. (1994) (36)
The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells (2014) (36)
Eukaryotic Translation Initiation Factor 3, Subunit a, Regulates the Extracellular Signal-Regulated Kinase Pathway (2011) (35)
p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. (2016) (35)
A model for the selective mode of action of the irreversible monoamine oxidase inhibitors clorgyline and deprenyl, based on studies of their ability to activate a Ca2+‐Mg2+ ATPase in defined lipid environments (1977) (35)
cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. (2006) (35)
Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. (1997) (35)
G-proteins as mediators of cellular signalling processes (1990) (35)
Purification, characterization and analysis of rolipram inhibition of a human type-IVA cyclic AMP-specific phosphodiesterase expressed in yeast. (1994) (34)
Compartmentalization of cyclic AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. (1995) (33)
A RSK(y) Relationship with Promiscuous PKA (2006) (33)
β-Arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of β2-adrenoceptor signalling to activation of ERK (2005) (33)
Activation and phosphorylation of the 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase by cyclic AMP-dependent protein kinase. (1989) (32)
The phorbol ester TPA inhibits cyclic AMP phosphodiesterase activity in intact hepatocytes (1986) (32)
Alterations in G-protein expression and the hormonal regulation of adenylate cyclase in the adipocytes of obese (fa/fa) Zucker rats. (1991) (30)
Glucagon, vasopressin and angiotensin all elicit a rapid, transient increase in hepatocyte protein kinase C activity. (1992) (30)
Membrane phosphorylation: a crucial role in the action of insulin, EGF, and pp60src? (1981) (30)
Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4). (2011) (30)
Surgically Induced Cryptorchidism-Related Degenerative Changes in Spermatogonia Are Associated with Loss of Cyclic Adenosine Monophosphate-Dependent Phosphodiesterases Type 4 in Abdominal Testes of Rats (2001) (30)
Okadaic acid identifies a phosphorylation/dephosphorylation cycle controlling the inhibitory guanine-nucleotide-binding regulatory protein Gi2. (1991) (29)
Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. (1995) (29)
Insulin stimulates a novel GTPase activity in human platelets (1987) (29)
Lysophosphatidylcholines can modulate the activity of the glucagon-stimulated adenylate cyclase from rat liver plasma membranes. (1979) (29)
Quinidine and melittin both decrease the fluidity of liver plasma membranes and both inhibit hormone-stimulated adenylate cyclase activity. (1987) (28)
The dg2 (for) gene confers a renal phenotype in Drosophila by modulation of cGMP-specific phosphodiesterase (2004) (28)
Epac and the high affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model (2014) (27)
Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. (2004) (27)
Treatment of streptozotocin-diabetic rats with metformin restores the ability of insulin to inhibit adenylate cyclase activity and demonstrates that insulin does not exert this action through the inhibitory guanine nucleotide regulatory protein Gi. (1988) (27)
Phosphorylation of calmodulin on Tyr99 selectively attenuates the action of calmodulin antagonists on type-I cyclic nucleotide phosphodiesterase activity. (1994) (27)
Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms (2013) (26)
Interaction of the human insulin receptor with the ras oncogene product p21 (1987) (26)
The Long and Short of Vascular Smooth Muscle Phosphodiesterase-4 As a Putative Therapeutic Target (2005) (26)
G‐protein linked receptors: a family probed by molecular cloning and mutagenesis procedures (1992) (26)
FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system (2017) (26)
Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change. (2008) (25)
A scanning peptide array approach uncovers association sites within the JNK/βarrestin signalling complex (2009) (25)
Cyclic Nucleotide Phosphodiesterase Superfamily (2006) (25)
Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners (2016) (25)
Regulation of cardiac adenylate cyclase activity in rodent models of obesity. (1992) (25)
Mixed substrate experiments with human brain monoamine oxidase. (1974) (25)
Changes in the phosphorylation state of the inhibitory guanine-nucleotide-binding protein Gi-2 in hepatocytes from lean (Fa/Fa) and obese (fa/fa) Zucker rats. (1990) (25)
Multiple defects occur in the guanine nucleotide regulatory protein system in liver plasma membranes of obese (fa/fa) but not lean (Fa/Fa) Zucker rats: loss of functional Gi and abnormal Gs function. (1989) (25)
Perturbations of liver plasma membranes induced by Ca2+ are detected using a fatty acid spin label and adenylate cyclase as membrane probes. (1983) (25)
Evolutionarily Conserved Role of Calcineurin in Phosphodegron-Dependent Degradation of Phosphodiesterase 4D (2010) (25)
The selective effects of charged local anaesthetics on the glucagon- and fluoride-stimulated adenylate cyclase activity of rat-liver plasma membranes. (1980) (25)
Alterations in G-protein expression, Gi function and stimulatory receptor-mediated regulation of adipocyte adenylyl cyclase in a model of insulin-resistant diabetes with obesity. (1992) (25)
Lipid substitution of mitochondrial monoamine oxidase can lead to the abolition of clorgyline selective inhibition without alteration in the A/B ratio assessed by substrate utilisation. (1980) (24)
Cell signalling: Dual control of adenylate cyclase (1983) (24)
Compartmentalized cAMP signalling regulates vasopressin-mediated water reabsorption by controlling aquaporin-2. (2005) (24)
Phosphodiesterases as Drug Targets (2011) (24)
Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function (2011) (24)
Genomic organisation of the human cyclic AMP-specific phosphodiesterase PDE4C gene and its chromosomal localisation to 19p13.1, between RAB3A and JUND. (1999) (23)
Reduced PDE4 expression and activity contributes to enhanced catecholamine‐induced cAMP accumulation in adipocytes from FOXC2 transgenic mice (2006) (23)
Specific antibodies and the selective inhibitor ICI 118233 demonstrate that the hormonally stimulated 'dense-vesicle' and peripheral-plasma-membrane cyclic AMP phosphodiesterases display distinct tissue distributions in the rat. (1987) (23)
Gi-2 is at the centre of an active phosphorylation/dephosphorylation cycle in hepatocytes: the fine-tuning of stimulatory and inhibitory inputs into adenylate cyclase in normal and diabetic states. (1991) (22)
An assessment of the ability of insulin-stimulated cyclic AMP phosphodiesterase to decrease hepatocyte intracellular cyclic AMP concentrations. (1984) (22)
Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression. (2014) (22)
Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase. (1997) (21)
The N-terminal alternately spliced regions of PDE4A cAMP-specific phosphodiesterases determine intracellular targeting and regulation of catalytic activity. (1996) (21)
Detergents modify the form of arrhenius plots of 5′‐nucleotidase activity (1978) (21)
The use of selective inhibitors and computer modelling to evaluate the role of specific high affinity cyclic AMP phosphodiesterases in the hormonal regulation of hepatocyte intracellular cyclic AMP concentrations. (1990) (21)
Insulin affects the ability of Gi to be ADP-ribosylated but does not elicit its phosphorylation in intact hepatocytes. (1989) (20)
The phorbol ester TPA prevents the expression of both glucagon desensitisation and the glucagon‐mediated block of insulin stimulation of the peripheral plasma membrane cyclic AMP phosphodiesterase in rat hepatocytes (1985) (20)
Desensitization of atriopeptin stimulated accumulation and extrusion of cyclic GMP from a kidney epithelial cell line (MDCK). (1991) (20)
Disrupting specific PDZ domain‐mediated interactions for therapeutic benefit (2009) (20)
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases (2016) (20)
Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains (2015) (20)
Effects of lactation on the signal transduction systems regulating lipolysis in sheep subcutaneous and omental adipose tissue. (1995) (20)
Submitochondrial localization and asymmetric disposition of two peripheral cyclic nucleotide phosphodiesterases. (1982) (20)
Molecular basis of insulin receptor function. (1989) (20)
Chronic effects of somatotropin treatment on response of subcutaneous adipose tissue lipolysis to acutely acting factors in vivo and in vitro. (1996) (19)
Beta-arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of beta2-adrenoceptor signalling to activation of ERK. (2005) (19)
Coupling of the glucagon receptor to adenylate cyclase. (1979) (19)
In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10). (2008) (19)
Insulin stimulates the tyrosyl phosphorylation and activation of the 52 kDa peripheral plasma-membrane cyclic AMP phosphodiesterase in intact hepatocytes. (1989) (19)
Exposure of mitochondrial outer membranes to neuraminidase selectively destroys monoamine oxidase A activity (1980) (18)
The activity of dopamine-stimulated adenylate cyclase from rat brain stratum is modulated by temperature and the bilayer-fluidizing agent, benzyl alcohol. (1982) (18)
Identification and selective inhibition of four distinct soluble forms of cyclic nucleotide phosphodiesterase activity from kidney. (1990) (18)
5′‐Nucleotidase is activated upon cholesterol‐depletion of liver plasma membranes (1983) (18)
Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression (2015) (18)
Subcellular localization and hormone sensitivity of adipocyte cyclic AMP phosphodiesterase. (1989) (18)
Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4) (2013) (17)
Insulin controls the cyclic AMP‐dependent phosphorylation of integral and peripheral proteins associated with the rat liver plasma membrane (1980) (17)
Regulation of intracellular cyclic AMP concentrations in hepatocytes involves the integrated activation and desensitization of adenylyl cyclase coupled with the action and activation of specific isoforms of cyclic AMP phosphodiesterase. (1992) (17)
Glucagon desensitization of adenylate cyclase and stimulation of inositol phospholipid metabolism does not involve the inhibitory guanine nucleotide regulatory protein Gi, which is inactivated upon challenge of hepatocytes with glucagon. (1989) (17)
The mediator is the message: is it part of the answer of insulin's action? (1986) (17)
Inhibition of beef plasma amine oxidase by clorgyline. (1975) (17)
Effects of Δ9-tetrahydrocannabinol on glucagon receptor coupling to adenylate cyclase in rat liver plasma membranes (1986) (17)
A role for protein kinase C-mediated phosphorylation in eliciting glucagon desensitization in rat hepatocytes. (1995) (17)
Bombesin stimulation of inositol 1,4,5-trisphosphate generation and intracellular calcium release is amplified in a cell line overexpressing the N-ras proto-oncogene. (1989) (16)
Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase. (1997) (16)
Hard times for oncogenic BRAF-expressing melanoma cells. (2011) (16)
Genetically acquired diabetes: adipocyte guanine nucleotide regulatory protein expression and adenylate cyclase regulation. (1991) (16)
The local anaesthetic and bilayer fluidising agent, benzyl alcohol decreases the thermostability of the integral membrane protein adenylate cyclase (1982) (16)
A mnemonical or negative-co-operativity model for the activation of adenylate cyclase by a common G-protein-coupled calcitonin-gene-related neuropeptide (CGRP)/amylin receptor. (1993) (15)
DISC1 regulates N-methyl-D-aspartate receptor dynamics: abnormalities induced by a Disc1 mutation modelling a translocation linked to major mental illness (2018) (15)
Renaissance for cyclic GMP (1985) (15)
Glucagon stimulates adenylate cyclase through GR2 glucagon receptors: a process which can be attenuated by glucagon stimulating inositol phospholipid metabolism through GR1 glucagon receptors. (1987) (15)
Co-transfection with protein kinase D confers phorbol-ester-mediated inhibition on glucagon-stimulated cAMP accumulation in COS cells transfected to overexpress glucagon receptors. (1997) (15)
Insulin and glucagon attenuate the ability of cholera toxin to activate adenylate cyclase in intact hepatocytes. (1988) (14)
The thermodependence of the activity of integral enzymes in liver plasma membranes (1982) (14)
Insulin activates the plasma-membrane and dense-vesicle cyclic AMP phosphodiesterase in hepatocytes by distinct routes. (1983) (14)
Cellular Functions of PDE4 Enzymes (2006) (14)
Peptide mapping of multiple forms of cyclic nucleotide phosphodiesterase. (1982) (14)
Metformin treatment of lean and obese Zucker rats modulates the ability of glucagon and insulin to regulate hepatocyte adenylate cyclase activity. (1989) (14)
Phosphorylation of RACK 1 on Tyrosine 52 by c-Abl Is Required for Insulin-like Growth Factor I-mediated Regulation of Focal Adhesion Kinase * (2009) (14)
Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. (2010) (14)
Amphoptericin B has very different effects on the glucagon‐ and fluoride‐stimulated adenylate cyclase activities of rat liver plasma membranes (1979) (14)
Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue. (1987) (13)
The lipid fluidity of rat liver membrane subfractions. (1983) (13)
Hypertension linked to PDE3A activation (2015) (13)
Investigation of extracellular signal-regulated kinase 2 mitogen-activated protein kinase phosphorylation and regulation of activity of PDE4 cyclic adenosine monophosphate-specific phosphodiesterases. (2005) (13)
A novel role for a Drosophila homologue of cGMP-specific phosphodiesterase in the active transport of cGMP. (2006) (13)
Cholera toxin requires oxidized nicotinamide-adenine dinucleotide to activate adenylate cyclase in purified rat liver plasma membranes. (1977) (13)
Intracellular compartmentalization of PDE4 cyclic AMP-specific phosphodiesterases. (1998) (13)
Amine competition for oxidation by rat liver mitochondrial monoamine oxidase. (1975) (13)
Alternative splicing of the type-IVA cyclic AMP phosphodiesterase gene provides isoform variants with distinct N-terminal domains fused to a common, soluble catalytic unit: 'designer' changes in Vmax, stability and membrane association. (1995) (13)
N6-(Phenylisopropyl)adenosine prevents glucagon both blocking insulin's activation of the plasma-membrane cyclic AMP phosphodiesterase and uncoupling hormonal stimulation of adenylate cyclase activity in hepatocytes. (1984) (13)
Cyclic AMP-dependent Transcriptional Up-regulation of Phosphodiesterase 4D5 in Human Airway Smooth Muscle Cells IDENTIFICATION OF A NOVEL PDE4D5 PROMOTER* (2002) (12)
Determination of G-protein levels, ADP-ribosylation by cholera and pertussis toxins and the regulation of adenylyl cyclase activity in liver plasma membranes from lean and genetically diabetic (db/db) mice. (1991) (12)
Insulin controls intracellular cyclic AMP concentrations in hepatocytes by activating specific cyclic AMP phosphodiesterases: phosphorylation of the peripheral plasma membrane enzyme. (1984) (12)
The insulin-stimulated cyclic AMP phosphodiesterase binds to a single class of protein sites on the liver plasma membrane. (1981) (12)
Extracellular calcium modulates insulin's action on enzymes controlling cyclic AMP metabolism in intact hepatocytes. (1993) (12)
Guanine nucleotide regulatory proteins in insulin's action and in diabetes. (1989) (12)
Mobile receptor and collision coupling mechanisms for the activation of adenylate cyclase by glucagon. (1981) (12)
Multi-site phosphorylation of the inhibitory guanine nucleotide regulatory protein Gi-2 occurs in intact rat hepatocytes. (1994) (12)
p62 (SQSTM1) forms part of a novel, reversible aggregate containing a specific conformer of the cAMP degrading phosphodiesterase, PDE4A4 (2010) (12)
Interaction of caspase-3 with the cyclic GMP binding cyclic GMP specific phosphodiesterase (PDE5a1). (2003) (11)
Regulation of a Drosophila melanogaster cGMP-specific phosphodiesterase by prenylation and interaction with a prenyl-binding protein. (2008) (11)
Resensitization of hepatocyte glucagon-stimulated adenylate cyclase can be inhibited when cyclic AMP phosphodiesterase inhibitors are used to elevate intracellular cyclic AMP concentrations to supraphysiological values. (1988) (11)
Streptozotocin-induced diabetes elicits the phosphorylation of hepatocyte Gi2 alpha at the protein kinase C site but not at the protein kinase A-controlled site. (1996) (11)
An insulin mediator preparation serves to stimulate the cyclic GMP activated cyclic AMP phosphodiesterase rather than other purified insulin-activated cyclic AMP phosphodiesterases. (1988) (11)
Acidic phospholipid species inhibit adenylate cyclase activity in rat liver plasma membranes. (1986) (11)
Pleiotypic responses: regulation by programmable messengers or by multiple receptors? (1986) (10)
Insulin activates a rat liver peripheral plasma-membrane cyclic AMP phosphodiesterase by a phosphorylation mechanism. (1980) (10)
Cross-talk between PI3-kinase and cAMP-Protein Kinase signaling pathways at the level of a Protein Kinase B / -arrestin / cAMP phosphodiesterase-4 complex (2010) (10)
PDE 4 B 5 , a Novel , Super-Short , Brain-Specific cAMP Phosphodiesterase-4 Variant Whose Isoform-Specifying N-Terminal Region Is Identical to That of cAMP Phosphodiesterase-4 D 6 ( PDE 4 D 6 ) (2007) (10)
Binding to GDP-agarose identifies a novel 60kDa substrate for the insulin receptor tyrosyl kinase in mouse NIH-3T3 cells expressing high concentrations of the human insulin receptor. (1989) (10)
Adipocyte plasma-membrane Gi and Gs in insulinopenic diabetic patients. (1989) (9)
Arrestin Times for Developing Antipsychotics and β-Blockers (2009) (9)
The local anaesthetic benzyl alcohol attenuates the alpha 2-adrenoceptor-mediated inhibition of human platelet adenylate cyclase activity when stimulated by prostaglandin E1, but not that stimulated by forskolin. (1989) (9)
Tosyl-lysyl chloromethylketone detects conformational changes in the catalytic unit of adenylate cyclase induced by receptor and G-protein stimulation. (1988) (9)
Insulin inhibits the phosphorylation of alpha-Gi-2 in intact hepatocytes. (1995) (9)
Identification of the pertussis and cholera toxin substrates in normal and N-ras transformed NIH3T3 fibroblasts and an assessment of their involvement in bombesin-stimulation of inositol phospholipid metabolism. (1989) (9)
Mechanism of glucagon activation of adenylate cyclase in the presence of Mn2+ (1983) (9)
The role of N-ras p21 in the coupling of growth factor receptors to inositol phospholipid turnover. (1987) (9)
Development of rolipram-sensitive, cyclic AMP phosphodiesterase (PDE4) in rat primary neuronal cultures. (2001) (9)
Understanding insulin action: Principles and molecular mechanisms (1990) (8)
Retracted: Phosphorylation of PDE4A5 by MAPKAPK2 attenuates fibrin degradation via p75 signalling (2019) (8)
Guanine-nucleotide-binding proteins in diabetes and insulin-resistant states. (1990) (8)
Regulation of the GTP-binding protein-based antilipolytic system of sheep adipocytes by growth hormone. (1998) (8)
Molecular cloning and transient expression in COS 7 cells of a novel human PDE 4 B cAMP-specific phosphodiesterase , HSPDE 4 B 3 (1997) (8)
Phosphodiesterase-4 gates the ability of protein kinase A to phosphorylate G-protein receptor kinase-2 and influence its translocation. (2006) (8)
The role of Gi and the membrane-fluidizing agent benzyl alcohol in modulating the hysteretic activation of human platelet adenylate cyclase by guanylyl 5'-imidodiphosphate. (1993) (8)
Phosphodiesterase 4A, cAMP specific (2006) (7)
Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. (2010) (7)
Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. (2017) (7)
The temperature dependence of adenylate cyclase activity solubilised using various Lubrol detergents. (1979) (7)
Heterogeneity of cyclic nucleotide phosphodiesterases in liver endoplasmic reticulum. (1983) (7)
Thermotropic lipid phase separations in human platelet and rat liver plasma membranes (2005) (7)
Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7). (2019) (7)
Does insulin exert certain of its actions through a distinct species of guanine nucleotide regulatory protein? (1984) (7)
Lysolecithin is a selective reversible inhibitor of mitochondrial monoamine oxidase. (1978) (7)
Erratum: Abolition of the expression of inhibitory guanine nucleotide regulatory protein Gi in diabetes (Nature (1987) 327, (229-232) (1987) (7)
Developmental changes in the form of the Arrhenius plots of rat liver plasma membrane adenylate cyclase and 5'-nucleotidase activities. (1982) (7)
The action of the local anaesthetic, benzyl alcohol and the monoamine oxidase inhibitor, clorgyline on the β‐hydroxybutyrate dehydrogenase activity of adult and weanling rat brain mitochondria (1978) (6)
Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats (2001) (6)
Analysis of mammalian ras effector function. (1988) (6)
Dimethylnitrosamine inhibits the glucagon-stimulated adenylate cyclase activity of rat liver plasma membranes and decreases plasma membrane fluidity. (1984) (6)
Dietary linoleic acid-induced changes in respiratory beta-adrenergic receptor function and the form of arrhenius plots of isoprenaline- and prostaglandin E2-stimulated adenylate cyclase activity in a model for atopy. (1994) (6)
Dependent Protein Kinase A Human T Lymphocytes Is Not Mediated by ( cAMP )-Dependent Inhibition of IL-5 from-Cyclic Monophosphate ′ , 5 ′ Adenosine 3 (2001) (6)
Treatment of intact hepatocytes with the calcium ionophore A23187 perturbs both the synthesis and the degradation of the second messenger cyclic AMP. Actions on adenylate cyclase and cyclic AMP phosphodiesterase activities. (1988) (6)
The MAP kinase ERK 2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE 4 D 3 by phosphorylating it at Ser 579 (2013) (6)
Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis. (2016) (6)
Proteolytic activation and solubilization of endoplasmic-reticulum cyclic AMP phosphodiesterase activity. (1983) (5)
The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes (2018) (5)
Analysis of the adenylate cyclase signalling system, and alterations induced by culture with insulin, in a novel SV40-DNA-immortalized hepatocyte cell line (P9 cells). (1994) (5)
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors. (2008) (5)
The effects of p21N-ras expression in NIH-3T3 cells upon cyclic AMP metabolism. (1989) (5)
A kinetic method for the detection of inhibitory contaminants in radioactive substrates. (1977) (5)
Phosphatidylinositol 5-phosphate 4-kinase (2012) (5)
a paradigm for understanding the unique non-redundant roles that PDE 4 isoforms play in shaping compartmentalized cAMP cell signalling (2007) (5)
Low Level Cyclic Adenosine 3',5'-Monophosphate Accumulation Analysis of (des-His',des- (1996) (5)
Abolition of the expression of inhibitory guanine nucleotide regulatory protein Gi in diabetes (1987) (5)
On the possible role of biliverdin stimulation of cyclic AMP levels as a trigger for liver regeneration in the rat. (1984) (5)
THE LATERAL ORGANISATION OF LIPIDS AROUND A CALCIUM TRANSPORT PROTEIN: EVIDENCE FOR A PHOSPHOLIPID ANNULUS THAT MODULATES FUNCTION (1976) (5)
The cAMP phosphodiesterase-4 D 7 ( PDE 4 D 7 ) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells (2014) (4)
Strategies for identifying functionally active domains upon cell surface receptors. (1989) (4)
Upregulation of cAMP-specific PDE-4 activity following ligation of the TCR complex on thymocytes is blocked by selective inhibitors of protein kinase C and tyrosyl kinases (1998) (4)
Effects of delta 9-tetrahydrocannabinol on glucagon receptor coupling to adenylate cyclase in rat liver plasma membranes. (1986) (4)
Chapter 15 Structure and function of the receptor for insulin (1988) (4)
THE NATURE OF THE ELECTROPHORETICALLY SEPARABLE FORMS OF MONOAMINE OXIDASE (1973) (4)
Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected]. (1995) (4)
Potentiates TCR Signaling Phosphodiesterase 4 to Lipid Rafts TCR-and CD 28-Mediated Recruitment of (2004) (4)
CHAPTER 22 – Insulin and Its Interaction with G Proteins (1990) (4)
Insulin and vasopressin elicit inhibition of cholera-toxin-stimulated adenylate cyclase activity in both hepatocytes and the P9 immortalized hepatocyte cell line through an action involving protein kinase C. (1995) (4)
Dual control of adenylate cyclase. (1983) (4)
Localization of the gene for the human serotonin 5-HT(2B) receptor to chromosome 2. (1996) (4)
A simple method for sequencing small DNAs by introducing precise overlapping ends into restriction digestion fragments. (1998) (4)
Phosphorylation of Heterotrimeric G-Protein (1993) (3)
Treatment of intact hepatocytes with synthetic diacyl glycerols mimics the ability of glucagon to cause the desensitization of adenylate cyclase (1991) (3)
Isolation and characterization of insulin-stimulated, high-affinity cAMP phosphodiesterases from rat liver. (1988) (3)
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status (2019) (3)
A better view of beta-receptors (1984) (3)
The cortico-striatal circuit regulates sensorimotor gating via Disc1/Huntingtin-mediated Bdnf transport (2018) (3)
The role of polybasic compounds in determining the tyrosyl phosphorylation of calmodulin by the human insulin receptor. (1993) (3)
Molecular genetic approaches. III. Determination of protein sequence motifs involved in protein targeting by use of coupled transcription-translation systems. (1998) (3)
Peptide mapping of cyclic nucleotide phosphodiesterases. (1984) (2)
SMALL MOLECULE AKAP/PKA INTERACTION DISRUPTORS THAT ACTIVATE PKA INTERFERE WITH COMPARTMENTALIZED cAMP SIGNALING IN CARDIAC MYOCYTES (2010) (2)
Cloning and characterisation of a novel cGMP-specific phosphodiesterase from Drosophila melanogaster (2003) (2)
Phosphorylation of Gi in intact cells. (1990) (2)
TYROSINE 302 IN RACK1 IS ESSENTIAL FOR IGF-I-MEDIATED COMPETITIVE BINDING OF PP2A AND β1 INTEGRIN AND FOR TUMOUR CELL PROLIFERATION AND MIGRATION (2008) (2)
The insulin-sensitivity of phosphodiesterase activities released by hypotonic extraction of hepatocyte particulate fractions (1989) (2)
Into STELLAR space (1988) (2)
Regulation of the phosphorylation state of Gi2 in intact rat hepatocytes. (1990) (2)
G-protein α-subunit mRNAs in diabetic rat tissues (1990) (2)
Some problems concerning the apparent multiplicity of monoamine oxidase [proceedings]. (1977) (2)
Explorer Disrupted in schizophrenia 1 and phosphodiesterase 4 B : towards an understanding of psychiatric illness (2017) (2)
Hormonal regulation of Gi2 alpha-subunit phosphorylation in intact hepatocytes. (1990) (2)
SUMOylation of DISC1: A Potential Role in Neural Progenitor Proliferation in the Developing Cortex (2016) (2)
Activation and Desensitization of Transducing Pathways (1990) (2)
The cyclic nucleotides. (2011) (2)
A novel method for the purification of the insulin-activated peripheral plasma membrane, high-affinity cyclic AMP phosphodiesterase (1986) (1)
The Function of the Mammalian Ras Proteins (1989) (1)
Regulation of sensorimotor gating via Disc1/Huntingtin-mediated Bdnf transport in the cortico-striatal circuit (2022) (1)
Regulation of cellular signal transduction pathways by densensitization and amplification (1994) (1)
Further evidence for the common ancestry of cytochrome b-..c complexes (1984) (1)
Expression of G-protein β-subunit in lean and obese Zucker rats and streptozotocin-induced diabetic and normal rats (1989) (1)
Development of lipid metabolism in ovine preadipocytes in vitro. (1997) (1)
Proteolysis of the 52 kDa, insulin-stimulated, peripheral, plasma-membrane cyclic AMP-specific phosphodiesterase (1989) (1)
Protein kinase C isoform expression during differentiation of 3T3-F442A preadipocytes. (1997) (1)
Glucagon activates two distinct signal transduction systems in hepatocytes, which leads to the desensitization of G-protein-regulated adenylate cyclase, the phosphorylation and inactivation of Gi-2 and the phosphorylation and stimulation of a specific cyclic AMP phosphodiesterase (1990) (1)
Modulation of adenosine signalling in sheep adipose tissue by growth hormone. (1995) (1)
Insulin alters the target size of the peripheral cyclic AMP phosphodiesterase but not the integral cyclic GMP-stimulated cyclic AMP phosphodiesterase in liver plasma membranes. (1990) (1)
Activation of the ‘dense-vesicle” cyclic AMP-phosphodiesterase from rat liver by cyclic AMP-dependent protein kinase (1988) (1)
Methods in Enzymology, Vol. 195: Adenylyl Cyclase, G Proteins and Guanylyl Cyclase: edited by Roger A. Johnson and Jackie D. Corbin, Academic Press, 1991. $69.00 (xxx + 512 pages) ISBN 0 12 182 096 3 (1991) (1)
Growth hormone suppresses the expression of Gi2 in rat adipocytes. (1993) (0)
A novel role for cGMP-specific phosphodiesterase, PDE6, in active transport of cGMP (2005) (0)
Functioning of the inhibitory regulation of adenylate cyclase in diabetic states: a reply. (1991) (0)
DISC 1 regulates N-methyl-D-aspartate receptor dynamics (2018) (0)
G-protein levels and function in human and experimental hypertension (1990) (0)
Correction for Bjørgo et al., “Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/β-Arrestin/cAMP Phosphodiesterase 4 Complex” (2022) (0)
Dynamic regulation of DISC1-PDE4 complexes may link camp signalling to neuronal pathways relevant to psychiatric illness (2005) (0)
Phosphodiesterase 4 Isoform Expression and Function in a Model of Macrophage Differentiation (2002) (0)
Crystal structure of PDE4A10 in complex with inhibitor NPV (2008) (0)
17-P003 Discovery of small molecules to control human embryonic stem cell fate (2009) (0)
PCAF Lysine Acetyltransferase (2008) (0)
between Rheb and Phosphodiesterase 4D Regulation of the Dynamic Interaction Cyclic AMP Controls mTOR through (2014) (0)
Effects of transformation by p21N-ras upon the inositol phospholipid and adenylate cyclase signaling pathways in NIH 3T3 cells. (1988) (0)
Fluorescence Resonance Energy Transfer–Based Analysis of cAMP Dynamics in Live Neonatal Rat Cardiac Myocytes Reveals Distinct Functions of Compartmentalized Phosphodiesterases Cellular Biology (2004) (0)
Blocking the phosphodiesterase isoform PDE4A5 in the hippocampus ameliorates plasticity and memory deficits induced by brief sleep deprivation (2012) (0)
The insulin receptor tyrosyl kinase fails to phosphorylate the guanine nucleotide regulatory proteins Ni, No and p21 (1986) (0)
438. Amyloidogenic DISC1: Role for Psychiatric Manifestation in Neurodegenerative Disorders (2017) (0)
Biochemical messengers: Hormones, neurotransmitters and growth factors: By D.G. Hardie; Chapman & Hill; London, 1991; x + 311 pages; £13.95 (1991) (0)
A Novel Form of Type-IV A cAMP Phosphodiesterase found in rat brain (1995) (0)
PTPe (RPTPe and Cyt-PTPe) (2012) (0)
Inhibition of PDE4 (Type 4) Cyclic AMP-specific Phosphodiesterase Isoforms (1997) (0)
N-TERMINAL SPLICE REGION OF RAT C-AMP PHOSPHODIESTERASE, NMR, 7 STRUCTURES (1997) (0)
Glucagon desensitisation of adenylate cyclase in hepatocytes: an action mediated by a distinct population of glucagon receptors coupled to inositol phospholipid metabolism (1987) (0)
Disrupted in schizophrenia 1 and phosphodiesterase 4B are genetic factors in schizophrenia that interact to regulate cAMP signalling (2005) (0)
Lipids and Membranes: past, present and future: J.A.F. Op Den Kamp, B. Roelofsen and K.W.A. Wirtz (Editors) Elsevier Biomed. Div., Amsterdam, 1986, pp. 380, $92.50 (1987) (0)
Title Inferring Signaling Pathway Topologies from MultiplePerturbation Measurements of Specific Biochemical Species (2018) (0)
Effects of MAP kinase (ERK2), and PKA phosphorylation upon the cyclic AMP specific phosphodiesterase HSPDE4D3 (1999) (0)
Compartmentalized Phosphodiesterase-2 Activity Blunts (cid:1) -Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway Cellular Biology (2006) (0)
Antisense technology reveals distinct roles for protein kinase C isoforms during 3T3-F442A preadipocyte differentiation. (1997) (0)
RACK1 is a highly conserved intracellular adaptor protein with significant homology to the beta subunit of hetero-trimeric G p (2008) (0)
Activation and Desensitization of Transducing Pathways (Nato ASI Series (closed) / Nato ASI Subseries H (2012) (0)
Desensitization of Glucagon-Stimulated Adenylate Cyclase is Mediated by Stimulation of Inositol Phospholipid Metabolism (1987) (0)
Uupregulation of High Affinity Cyclic AMP Phosphodiesterase (PDE) Genes Following BALloon Catheter Deendothelialization (Bal) in Rat Aorta (2000) (0)
Withdrawal: Mdm2 directs the ubiquitination of β-arrestin-sequestered cAMP phosphodiesterase-4D5 (2020) (0)
The Translation Factor eIF3a Regulates the Extracellular Signal regulated 1 Kinase (ERK) Pathway 2 (2017) (0)
‘Cross-Talk’ and the Regulation of Repatocyte Adenylate Cyclase Activity: Desensitization, G1 and Cyclic AMP Phosphodiesterase Regulation (1990) (0)
Editorial: Reflections on being 'founding' Editor-in-Chief of Cellular Signalling. (2015) (0)
CCDC 808534: Experimental Crystal Structure Determination (2012) (0)
The structure of the RACK1 interaction sites located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5. (2001) (0)
IDENTIFICATION OF A NEW PDE2A ISOFORM AND EXPRESSION OF PDE2 IN A SUBSET OF OLFACTORY NEURONS & GASTROINTESTINAL CELLS (1996) (0)
Activation of Phosphodiesterase 3A: New Hope for Cardioprotection. (2022) (0)
Are you getting the message? Cell signalling: by N.G. Morgan, Open University Press, 1989. £35.00 (hbk) £14.95 (pbk) (xii + 203 pages) ISBN 0 335 15820 X (1990) (0)
The cAMP phosphodiesterase, PDE4A5, is cleaved by caspase-3, downstream of its SH3 binding domain (2001) (0)
MEK1 binds directly to βarrestin1, influencing both its phosphorylation by ERK and the timing of its isoprenaline-stimulated internalization. (2009) (0)
DYNAMIC INTERACTIONS LINKING DISRUPTEDIN-SCHIZOPHRENIA 1 (DISC1) AND CAMP SPECIFIC PHOSPHODIESTERASE-4 ISOFORMS (2008) (0)
Abstract 3955: Identification of RACK1 as a novel regulatory subunit of PP2A (2010) (0)
Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Overview of PDEs and Their Regulation Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular Syste (2007) (0)
Regulation and development of membrane transport processes (Society of General physiologists series, Vol. 39): edited by James S. Graves, John Wiley & Sons, 1985. £48.30 (xiv + 287 pages) ISBN 0 471 81038 X (1986) (0)
PC-1 (Human) (2012) (0)
Insulin inhibits the phosphorylation of a-G,-2 in intact hepatocytes (2005) (0)
Coaggregation of DISC1 and mutant huntingtin dysregulates PDE4 in Huntington’s disease (2017) (0)
Membrane-mediated responses to 12-O-tetradecanoylphorbol-13-acetate in human skin fibroblasts. (1984) (0)
BOOK REVIEWS: Molecular and cellular approaches to the analysis of plant embryo development from somatic cells in vitro (1975) (0)
Guanosine 5'-triphosphate and guanosine 5'-[beta gamma-imido]triphosphate effect a collision coupling mechanism between the glucagon receptor and catalytic unit of adenylate cyclase. (1980) (0)
Lyn tyrosyl kinase binds to the human cAMP-specific phosphodiesterase pde46 (HSPDE4A4B) and causes a conformational change in its catalytic unit (1999) (0)
A good little book on enzymes: Control of Enzyme Activity by Philip Cohen, 2nd End (Outline Studies in Biology), Chapman & Hall, 1983. £2.95 (vi + 96 pages) ISBN 0 412 25560 X (1984) (0)
Selective regulation of PDE3A isoforms by differential phosphorylation (2013) (0)
Bolger, Graeme B. and Dunlop, Allan J. and Meng, Dong and Day, Jon P. and Klussmann, Enno and Baillie, George S. and Adams, David R. and Houslay, Miles D. (2015) Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells (2018) (0)
The search for a molecular mechanism for the action of insulin (1984) (0)
Modelling the cAMP pathway using BioNessie, and the use of BVP techniques for solving ODEs (2007) (0)
Validation of cAMP phosphodiesterase-4D7 (PDE4D7) for its independent contribution to risk stratification in a prostate cancer patient cohort with longitudinal biological outcomes. (2017) (0)
Mdm2 directs the ubiquitination of β-arrestin-sequestered cAMP phosphodiesterase-4D5. (2009) (0)
Prostanoid Receptor cAMP Signaling-Adrenoceptor 2 β Microdomains during Cross-talk in Discrete Subcellular Dynamic Regulation , Desensitization , and Mechanisms of Signal Transduction : (2007) (0)
G-protein alpha-subunit mRNAs in diabetic rat tissues. (1990) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Miles D. Houslay?

Miles D. Houslay is affiliated with the following schools:

University of Strathclyde
University of Manchester Institute of Science and Technology
University of Oxford
University of Edinburgh
University of Glasgow
King's College London
University of Helsinki
University of Cambridge

Miles D. Houslay's Academic­Influence.com Rankings

Why Is Miles D. Houslay Influential?

Miles D. Houslay's Published Works

Published Works

What Schools Are Affiliated With Miles D. Houslay?

Miles D. Houslay's AcademicInfluence.com Rankings